- Email:
High-Throughput Phenotypic Screening Service
Introduction
High-Throughput Phenotypic Screening employs a physiology-first strategy and supports large-scale analysis of genetic and chemical factors in neural systems. Creative Biolabs offers this service using human iPSC‑derived organoids and advanced 3D imaging to identify bioactive compounds. The service provides high‑resolution phenotypic and functional data, validates candidates in physiologically relevant models, and helps discover drugs for neurological disorders with improved clinical translatability.
Discover How We Can Help - Request a Consultation →
High-Throughput Phenotypic Screening Service
High-Throughput Phenotypic Screening enables large-scale, unbiased evaluation of cellular and functional phenotypes in neuronal models. It integrates automated imaging, multi-parameter analysis, and high-content detection to support efficient compound screening, disease modeling, and target validation.
Key Advantages
- High-efficiency automated workflow for large-scale sample processing
- Multi-parameter phenotypic quantification for full-scale profiling
- Compatible with 2D/3D neuronal models and iPSC-derived systems
- High sensitivity for subtle phenotypic changes
- Robust data analysis and reproducible results
Applications
- Neuroprotective and neurotoxic compound screening
- Anti-epileptic and CNS drug candidate evaluation
- Phenotypic analysis in neurodegenerative disease models
- Neuronal development and maturation assessment
- Phenotype‑driven target identification and validation
Workflow
What We Can Offer
At Creative Biolabs, we understand that no two drug discovery projects are identical. We provide a highly customizable and robust screening ecosystem designed to meet the rigorous demands of modern neuropharmacology.
End-to-End Customized Assay Development
Bespoke phenotypic endpoints tailored to your specific disease hypothesis, from synaptic plasticity to complex glial neuroinflammation models.
Diverse Library Access & Management
Expertise in screening diverse chemical spaces, including small molecules, natural products, and targeted genomic libraries (siRNA/shRNA/gRNA).
Advanced "New Approach Methodologies" (NAMs)
Implementation of human iPSC-derived neurons, 3D brain organoids, and zebrafish models to ensure superior physiological relevance.
Proprietary High-Content Analysis (HCA)
Application of deep-learning algorithms for automated image analysis, enabling the detection of subtle sub-cellular changes that traditional methods miss.
Scalable In Vivo CRISPR Screening
Cutting-edge CrAAVe-seq technology for validating essential neuronal genes and drug leads directly in mammalian brain tissue.
Stringent Quality Assurance & Data Integrity
Well-established quality systems and process analytical techniques (PAT) to ensure the stability and reproducibility of complex biological models.
Regulatory-Forward Solutions
All screening protocols follow the basic principles of Good Manufacturing Practice (GMP) where applicable and adhere strictly to the 3Rs principle for ethical research.
Experience the Creative Biolabs Advantage - Get a Quote Today →
Customer Reviews
FAQs
Q1: How does your phenotypic screen compare to traditional target-based screening?
A: Unlike target-based approaches that focus on a single protein, our phenotypic screens observe the global effect of a drug on a disease-relevant system. This allows for the discovery of leads for diseases with unknown targets and identifies compounds with beneficial polypharmacology.
Q2: What is the advantage of using zebrafish brain organoids in a screen?
A: Zebrafish organoids develop faster than human models and allow for whole-mount imaging without tissue sectioning. They serve as an excellent high-throughput bridge for early-stage toxicity and efficacy testing.
Q3: Can you handle custom cell lines provided by our lab?
A: Yes. We frequently integrate client-provided patient-derived iPSCs or proprietary cell lines into our automated HTPS workflow after a brief optimization phase.
Q4: Is the CrAAVe-seq platform compatible with all neuronal subtypes?
A: Our CrAAVe-seq platform utilizes Cre-dependent or cell-type-specific promoters, allowing us to target genetic perturbations to specific populations such as dopaminergic, GABAergic, or glutamatergic neurons.
Q5: What measures are taken to ensure the reproducibility of 3D organoid screens?
A: We use standardized protocols and automated liquid handling to minimize batch-to-batch variation, ensuring that each organoid in the screen meets rigorous quality control metrics for regional specification and maturity.
Creative Biolabs offers a world-class High-Throughput Phenotypic Screening platform that bridges the gap between basic research and clinical reality. Our combination of human iPSC technology, 3D organoid modeling, and innovative in vivo CRISPR screening provides the biological depth required to solve the most difficult CNS challenges.
Contact Our Team for More Information and to Discuss Your Project →
For Research Use Only. Not For Clinical Use.